SPIRIT III: Evaluation of the XIENCE V Everolimus-Eluting Stent -- Clinical, Angiographic, and IVUS Results

Luis Gruberg, MD, FACC


April 27, 2007

  Presenter: Gregg W. Stone, MD (Columbia University Medical Center, New York, NY), on Behalf of the SPIRIT III Investigators

The XIENCE V drug-eluting stent system (Abbott, Abbott Park, Illinois) releases everolimus from a thin cobalt-chromium stent strut covered by a durable biocompatible fluoropolymer. The SPIRIT II trial found that the XIENCE V stent had a significantly lower late loss compared with the TAXUS paclitaxel-eluting stent (Boston Scientific, Natick, Massachusetts).

The SPIRIT III trial was designed as the US pivotal approval study for the XIENCE V stent.

Study Design

A total of 1002 patients were enrolled at 65 centers in the United States. Patients with a reference vessel diameter ≥ 2.5 mm and ≤ 3.75 mm and a lesion length ≤ 28 mm were randomized in a 2:1 fashion to either the XIENCE V stent (n = 669) or the TAXUS stent (n = 333). Patients were treated with dual antiplatelet therapy for at least 6 months. The study was designed to show noninferiority and superiority. Angiographic follow-up was obtained in 77% of patients.

Primary endpoint: In-segment late loss at 8 months.

Secondary endpoints: Ischemia-driven target vessel failure defined as cardiac death, myocardial infarction, and vessel revascularization at 9 months.


Baseline clinical characteristics are shown in Table 1 , and baseline lesion characteristics are shown in Table 2 .

The primary endpoint of the study -- late loss at 8-month angiographic follow-up -- was 0.28 ± 0.48 mm in the TAXUS arm and 0.14 ± 0.41 mm in the XIENCE V stent, which met both the noninferiority (P < .0001) and superiority (P = .004) endpoints. Binary restenosis rates were lower in the XIENCE V stent group, although the difference did not achieve statistical significance (Figure).


SPIRIT III: binary restenosis at 8-month follow-up.

At 9-month clinical follow-up, the rates of target vessel failure, each of its individual components, and the rate of major adverse cardiac events were lower in patients treated with the XIENCE V stent ( Table 3 ). Stent thrombosis at 270 days was rare in both groups, and the rate of all-cause mortality was also low ( Table 3 ).


  1. The everolimus-eluting XIENCE V stent was both noninferior and superior to the TAXUS paclitaxel-eluting stent in reducing in-segment late loss (primary endpoint).

  2. The XIENCE V stent significantly reduced in-stent late loss at 8 months and reduced angiographic follow-up diameter stenosis with a strong trend toward lower binary restenosis.

  3. The XIENCE V stent demonstrated noninferior rates of target vessel failure at 9 months, with a significant 44% reduction in major adverse cardiovascular events. It also showed a strong trend toward reduced ischemia-driven target lesion revascularization, with a significant reduction in any target lesion revascularization.


The results of SPIRIT III, which will be used to seek US market approval of the XIENCE V stent showed that the stent has minimal late loss, which was reflected by the low rates of restenosis and target lesion revascularization. Unfortunately, a large number of patients did not undergo angiographic follow-up. The clinical outcome of patients was very good, although the study was not powered to detect a significant difference in these endpoints. The low rates of stent thrombosis will need to be addressed during the long-term follow-up of these patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.